AstraZeneca
multiple high value phase in laura expanding as backbone in early stage echo first to show overall survival trend amplify securing leadership with finite treatment option destiny breast moving into benefit in her first and only to show survival benefit in first regimen to extend survival in muscle invasive bladder cancer first to show benefit in nasal polyps adult extends strong clinical benefit to adult patient population with high unmet need indication expansion opportunities above represent combined pyr | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
7 of 38
Related slides by other companies
D-Wave
Investor Presentation
December 2023
advancements in coherence and connectivity also show business benefits | D-Wave
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io